Department of Pediatric Metabolism, Faculty of Medicine, Gazi University, Ankara, Turkey.
Department of Pediatric Cardiology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Turk J Med Sci. 2022 Dec;52(6):1900-1905. doi: 10.55730/1300-0144.5537. Epub 2022 Dec 21.
Vitamin D insufficiency is a common public health problem that is often unrecognized in children with congenital heart disease, and is not generally evaluated at congenital heart disease (CHD) follow-up. Recent studies have suggested that inadequate vitamin D status may have an adverse effect on cardiovascular health. This study investigates the relationship between vitamin D levels and hemodynamic parameters in children with CHD.
Included in the study 40 patients (25 females, 15 males) with CHD, who were evaluated for Ross heart failure score, vitamin D, parathyroid hormone (PTH), calcium, phosphorus, alkaline phosphatase (ALP), whole blood count (WBC) and echocardiographic measurements, and all measurements were repeated in the third month of the therapy.
The mean vitamin D level was 16.4 ± 6.6 ug/L before and 27.5 ± 9.9 μg/L in the third month of therapy, while the mean PTH level was 53.3 ± 34.9 pg/mL before and 43.8 ± 21.4 pg/mL in the third month of therapy. The mean WBC was 8084 ± 2324/µL before and 7378±1893/µL in the third month of the therapy, and the mean platelet (PLT) count was 280,897 ± 80,119/µL before and 307,179 ± 60,202/µL in the third month of the therapy. The mean ejection fraction (EF) was 64% ± 7.2% before and 66.7% ± 6.2% in the third month of therapy, while the right ventricle (RV) myocardial performance index (MPI) was 32.1% ± 6.7% before and 28.9% ± 6.5% in the third month of the therapy. IL10 level was increased in four patients in the third month of therapy. A statistically significant decrease in PTH level and WBC, and an increase in PLT number and IL-10 level were detected by the therapy. Furthermore, echocardiographic findings revealed a statistically significant increase in EF and a decrease in RVMPI attributable to the therapy.
The decreased levels of PTH, which is a proinflammatory marker, the increases in IL-10, which is an antiinflammatory cytokine, and the decreases in the number of WBC resulting from vitamin D treatment demonstrate the antiinflammatory effects of vitamin D. An improvement in EF means improvement in left ventricular contractility, while a decrease in RV MPI has been shown to improve the systolic and diastolic function of the right ventricle. These results suggest that vitamin D therapy has a positive effect on the heart, and so vitamin D levels should be evaluated during the routine follow-up of congenital heart disease.
维生素 D 不足是常见的公共健康问题,在患有先天性心脏病的儿童中常常未被识别,且在先天性心脏病(CHD)随访中通常未被评估。最近的研究表明,维生素 D 状态不足可能对心血管健康产生不良影响。本研究旨在调查 CHD 患儿的维生素 D 水平与血液动力学参数之间的关系。
研究纳入 40 名 CHD 患儿(女性 25 名,男性 15 名),评估其罗斯心力衰竭评分、维生素 D、甲状旁腺激素(PTH)、钙、磷、碱性磷酸酶(ALP)、全血细胞计数(WBC)和超声心动图测量值,所有测量值在治疗的第三个月重复。
治疗前,患儿的平均维生素 D 水平为 16.4 ± 6.6 ug/L,治疗第三个月时为 27.5 ± 9.9 μg/L;治疗前,患儿的平均 PTH 水平为 53.3 ± 34.9 pg/mL,治疗第三个月时为 43.8 ± 21.4 pg/mL。治疗前,患儿的平均 WBC 为 8084 ± 2324/µL,治疗第三个月时为 7378±1893/µL;治疗前,患儿的平均血小板(PLT)计数为 280,897 ± 80,119/µL,治疗第三个月时为 307,179 ± 60,202/µL。治疗前,患儿的平均射血分数(EF)为 64% ± 7.2%,治疗第三个月时为 66.7% ± 6.2%;治疗前,患儿的右心室(RV)心肌做功指数(MPI)为 32.1% ± 6.7%,治疗第三个月时为 28.9% ± 6.5%。在第三个月的治疗中,有 4 名患者的 IL10 水平升高。通过治疗,发现 PTH 水平、WBC 数量显著降低,PLT 数量和 IL-10 水平显著增加。此外,超声心动图检查结果显示,EF 显著增加,RVMPI 显著降低,这归因于治疗。
PTH 水平降低,PTH 是一种促炎标志物,IL-10 增加,IL-10 是一种抗炎细胞因子,WBC 数量减少,这些都是维生素 D 治疗的抗炎作用的证据。EF 的改善意味着左心室收缩力的改善,而 RVMPI 的降低已被证明可改善右心室的收缩和舒张功能。这些结果表明,维生素 D 治疗对心脏有积极影响,因此应在先天性心脏病的常规随访中评估维生素 D 水平。